

**BONESUPPORT PRESS RELEASES - 2015**

**December 10, 2015**

[BONESUPPORT™ Announces Results Of CERAMENT™ | BONE VOID FILLER Prospective Pilot Study Demonstrating Complete Bone Remodeling In Benign Bone Tumors](#)

**November 13, 2015**

[BONESUPPORT™ To Present Corporate Overview at Stifel 2015 Healthcare Conference](#)

**October 20, 2015**

[First U.S. Study Of CERAMENT™ Antibiotic Eluting Bone Substitute In The Management Of Chronic Osteomyelitis Presented At EBJIS](#)

**October 6, 2015**

[New Data From Oxford University Hospitals Demonstrate Superior Outcome With CERAMENT™ Antibiotic Eluting Bone Substitute Compared To Collagen And Calcium Sulfate In The Management Of Chronic Osteomyelitis](#)

**September 24, 2015**

[CERAMENT™ Antibiotic Eluting Bone Substitutes For The Management Of Osteomyelitis Prominent At The 34th Annual Meeting Of The European Bone & Joint Infection Society \(EBJIS\)](#)

**August 25, 2015**

[CERAMENT™ With Antibiotics To Be Featured Extensively At The 34th Annual Meeting Of The European Bone & Joint Infection Society \(EBJIS\)](#)

**June 23, 2015**

[CERAMENT™ Study Recognized At The 16th EFORT Congress In Prague](#)

**May 27, 2015**

[CERAMENT™ | G Shown To Increase Bone Formation And Decrease Infection](#)

**May 13, 2015**

[BONESUPPORT Earns Frost & Sullivan's 2015 Best Practices Award For Its Novel Product, CERAMENT™](#)

**April 29, 2015**

[BONESUPPORT Announces CE-Mark of CERAMENT™ |V, the First Injectable Vancomycin Eluting Bone Substitute in the Management of Osteomyelitis](#)

**April 23, 2015**

[Orthopedics This Week Biologics Feature focused on CERAMENT™ |G disruptive technology](#)

**April 15, 2015**

[BONESUPPORT Closes \\$14 Million In Funding Led By Major Scandinavian Pension Fund](#)

**February 25, 2015**

[BONESUPPORT Receives Approval to Market CERAMENT™ in India](#)

#### **Notes to Editor**

##### About BONESUPPORT™

BONESUPPORT AB has developed CERAMENT™ as an innovative range of radiopaque injectable osteoconductive bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to twelve months. Our products are effective in treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery. Our lead product, CERAMENT™ |BONE VOID FILLER (BVF) addresses important issues facing health care providers, such as avoiding hospital readmissions and revision surgery that result from failed bone healing and infection caused by residual bone voids. CERAMENT™ |BVF is commercially available in the U.S., EU, S.E. Asia and the Middle East.

CERAMENT™'s distinctive properties as a drug eluting material have been validated in clinical practice by CERAMENT™ |G and CERAMENT™ V, the first CE-marked injectable antibiotic eluting bone graft substitutes. These products provide local sustained delivery of gentamicin and vancomycin, respectively. The local delivery feature enables an initial high concentration of antibiotics to the bone defect and then a longer sustainable dose above the minimal inhibitory concentration (MIC) to protect bone healing and promote bone remodeling.

CERAMENT™ |G and CERAMENT™ V have demonstrated good results in patients with problematic bone infections including osteomyelitis. They are also used prophylactically in patients who are at risk for developing infection. CERAMENT™ |G and CERAMENT™ V are available in the EU.

BONESUPPORT AB was founded in 1999 by Prof. Lars Lidgren, an internationally respected scientist who has been the President of various musculoskeletal societies. BONESUPPORT's mission is to bring people with bone and joint diseases back to an active life. The company is based in Lund, Sweden.

*BONESUPPORT™ is a registered trademark.*

#### **Contact Information**

**Citigate Dewe Rogerson**

## PRESS RELEASE



David Dible, Andrea Bici, Mark Swallow  
+44 (0)20 7282 2949/1050/2948  
[bonesupport@citigatedr.co.uk](mailto:bonesupport@citigatedr.co.uk)